GlassScriptPhysician profile
Lee Thi Phan
NPI 1790458552
$7,882.10
in general payments reported to CMS, 2019-2025
26 companies · $5,473 in 2025
The $5,473 reported for 2025 was more than what 99% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $715 · 2023: $143 · 2024: $1,552 · 2025: $5,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,866 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,866.02 |
| Education | $301.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,327.09 | 2022-2025 | Nemluvio, Aklief, Dysport |
| Abbvie INC. | $1,262.89 | 2024-2025 | |
| Ucb, INC. | $1,051.17 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $876.61 | 2024-2025 | Tremfya |
| Genzyme Corporation | $512.48 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $478.25 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $348.28 | 2024-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $250.35 | 2024-2025 | Dupixent |
| Tela Bio, INC. | $228.22 | 2022 | |
| Sun Pharmaceutical Industries INC. | $198.64 | 2025 | |
| Amgen INC. | $189.04 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $186.80 | 2024-2025 | Sotyktu |
| Mentor Worldwide LLC | $171.87 | 2022-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Lilly USA, LLC | $156.08 | 2024-2025 | Ebglyss, Taltz |
| Allergan, INC. | $149.80 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $123.54 | 2024 | |
| Medtronic, INC. | $71.43 | 2022 | |
| Almirall LLC | $64.29 | 2025 | Klisyri, Seysara |
| Novartis Pharmaceuticals Corporation | $43.69 | 2025 | |
| Biofrontera INC. | $34.26 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $33.57 | 2025 | Vtama |
| Incyte Corporation | $29.39 | 2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $26.62 | 2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $24.65 | 2025 | |
| Botanix Sb INC | $23.85 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.24 | 2024 | Duobrii, Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.